<DOC>
	<DOC>NCT02211859</DOC>
	<brief_summary>Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.</brief_summary>
	<brief_title>Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: Patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment Evaluable tumour deposits Age 18 years or older Life expectancy of at least six months Written informed consent consistent with international conference of harmonization (ICH) good clinical practice (GCP) and local legislation Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2 Full recovery from all therapyrelated toxicities from previous chemo, hormone, immuno, or radiotherapies Serious illness or concomitant nononcological disease considered by the investigator to be incompatible with the protocol Pregnancy or breastfeeding Active infectious disease Known brain metastases Second malignancy requiring therapy Absolute neutrophil count less than 1500/mm3 Platelet count less than 100 000/mm3 Bilirubin greater than 1.5 mg/dl (&gt; 26 μmol/L) Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal) Serum creatinine greater than 1.5 mg/dl (&gt; 132 μmol/L) Women and men who are sexually active and unwilling to use a medically acceptable method of contraception Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>